Text/HTML

Latest News

News & Event inside

  • General Atlantic to Invest US$55 Million in Kalbe Genexine Biologics

    Capital to fuel Company’s strategic growth into a leading biologics platform in the Southeast Asia region

    Wednesday, January 27, 2021
    General Atlantic to Invest US$55 Million in Kalbe Genexine Biologics

    Jakarta, Indonesia – January 27, 2021 – Kalbe Genexine Biologics (“KGBio” or “the Company”), a leading integrate biologics holding company focused on the in-licensing, clinical development,  and manufacturing of novel biologicals and biosimilar molecules, today announced that General Atlantic, a leading global growth equity firm, will invest US$55 million in primary capital in the Company. The investment will support KGBio's ongoing clinical development and commercialization needs, asset acquisition plan, and production capacity expansion efforts. 

  • Kalbe Support Cervical Cancer Awareness Month

    Time for Cervical Cancer Screening

    Saturday, January 16, 2021
    Kalbe Support Cervical Cancer Awareness Month

    Jakarta, January 16, 2021 – PT Kalbe Farma Tbk (Kalbe) through the One Onco division along with the Indonesian Cancer Care Community (ICCC) and the Indonesian Cancer Foundation (YKI) of West Java, and is also supported by KALGen INNOLAB; conducted an online education event to commemorate the Cervical Cancer Awareness Month 2021 through a webinar themed 'Time for Cervical Cancer Screening' with speaker dr. Gatot N.A. Winarno, Sp.OG(K), M.Kes. 

  • Kalbe Launches Genetic Testing FitGENME Diet and Exercise

    Saturday, January 9, 2021
    Kalbe Launches Genetic Testing FitGENME Diet and Exercise

    Jakarta, 9 January 2021 – PT Kalbe Farma Tbk (Kalbe) today through one of its subsidiaries, Kalgen Innolab, launched the newest genetic testing methods, FitGENME; which consist of 2 types of tests; FitGENME Diet and FitGENME Sports. FitGENME Diet is a genetic test that can analyze variations in the DNA that are associated with the metabolism of a nutrient. While FitGENME Sports is a genetic test that can analyze variations in DNA that are associated with the metabolism of the body against certain types of sports. 

  • Kalbe Gets Phase-2 Clinical Trial Approval on COVID-19 Drug - GX17

    Wednesday, December 30, 2020
    Kalbe Gets Phase-2 Clinical Trial Approval on COVID-19 Drug - GX17

    Jakarta, 30 December 2020 - PT Kalbe Farma Tbk (Kalbe) through its subsidiary PT Kalbe-Genexine Biologics (KGBio) today has received approval for a clinical trial (PPUK) from the Food and Drug Administration of the Republic of Indonesia (BPOM) to carry out Phase 2 clinical trials of the drug GX-17, which is an immunotherapeutic drug that will be developed as a treatment for COVID-19 patients. BPOM has issued approval to KGBio to conduct a phase-2 clinical trial based on safety and effectiveness data from a previous study conducted by Genexine with IMAB in South Korea.

  • Continue to Innovate for better Health

    Wednesday, December 23, 2020
    Continue to Innovate for better Health

    Jakarta, December 23, 2020 – PT Kalbe Farma Tbk (“Kalbe” or the “Company”) held the Company's Extraordinary General Meeting of Shareholders (“EGMS”) which was held on 23 December 2020 at the Kalbe Business Innovation Center Building, Pulogadung, Jakarta. 

RSS
12345Last